At least one imageable tumor greater than or equal to 15 mm in the longest diameter
Confirmed diagnosis of cancer with a high likelihood of response to immuno-oncology therapy (melanoma or non-small cell lung cancer, or other malignancies with sponsor approval) and planned mono- or combination therapy with immuno-oncology therapy
Life expectancy of greater than 6 months
At least one imageable tumor greater than or equal to 15 mm in the longest diameter or a tumor assessable by PET in the opinion of the radiologist
Received treatment with an immune checkpoint inhibitor with evidence of response
Life expectancy of greater than 6 months
You may not be if
Subjects who plan to receive chemotherapy or radiation therapy during study participation
Prior history of failed immune checkpoint inhibitor therapy
Subjects who require steroid or other immunosuppressive medications within 2 weeks of the PET scan.
Females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using effective methods of contraception. Females of childbearing potential must not be pregnant or breastfeeding at screening and agree to avoid becoming pregnant for 24 hours following study drug administration.
Females and males must agree to refrain from sexual activity or to use effective contraceptive methods for 24 hours following study drug administration and during study participation
Clareo Health | Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
